Drugs / Nituzumab
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06414577 | May 2024 → Mar 2025 overdue | nasopharyngeal carcinoma | XIANG YANQUN | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06455072 | Feb 2023 → Jan 2025 | cervical cancer | Fujian Cancer Hospital | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nituzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06414577 ↗ |
| Modality | Monoclonal antibody | “Nituzumab is a humanized monoclonal antibody that binds to the epidermal growth factor receptor.” NCT06455072 ↗ |
| Route | Intravenous | “nituzumab given at a dose of 400 mg via intravenous injection” NCT06414577 ↗ |
| Target | EGFR | “EGFR monoclonal antibody” NCT06455072 ↗ |